Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage
Occasionally, patients may experience mild gastrointestinal upset or headache related to the niacinamide component
Using all three targets several pathways to boost growth hormone release at the same time
Add-ons can give you a much-needed boost or help address specific symptoms
What starting dose will my doctor pick
US$ 20.11
US$ 24.09
US$ 26.15
